A Form 4 filed with the SEC on September 11, 2026, discloses that Robert E. Landry, a director of Cytokinetics Inc (NASDAQ:CYTK), sold 1,000 shares of common stock on September 11, 2026, pursuant to a Rule 10b5-1 trading plan.
Key Highlights
- Reporting person: Robert E. Landry, identified as a Director of Cytokinetics Inc.
- Transaction: 1,000 shares of common stock disposed of (sold) on September 11, 2026.
- Sale price: $74.66 per share.
- Remaining ownership: 9,184 shares of common stock held directly following the transaction.
- Rule 10b5-1 plan: The filing indicates the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Robert E. Landry's Share Sale and Post-Transaction Position at Cytokinetics
According to the filing, Robert E. Landry, a director of Cytokinetics Inc, disposed of 1,000 shares of the company's common stock on September 11, 2026, at a price of $74.66 per share. The transaction is coded "S" in the filing, indicating a sale. The form was signed by John O. Faurescu as attorney-in-fact for Mr. Landry and was dated September 11, 2026.
The filing notes that a box has been checked to indicate the transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Following the reported sale, the filing discloses that Landry directly beneficially owned 9,184 shares of Cytokinetics common stock. No derivative securities transactions were reported in Table II of the filing.
What Was Disclosed
The filing reports a single sale of 1,000 shares of Cytokinetics Inc common stock by director Robert E. Landry at $74.66 per share on September 11, 2026, conducted under a Rule 10b5-1 plan, leaving him with 9,184 directly held shares.



Please wait processing your request...